Q32 Bio Prices $200 Million Public Offering of Common Stock and Pre-Funded Warrants

Q32 Bio Inc. (Nasdaq:
QTTB), a clinical-stage biotechnology company focused on alopecia areata and other autoimmune diseases, has priced an underwritten public offering raising about $200 million through common stock and pre-funded warrants.

The company is selling 6,027,399 shares of common stock at $18.25 per share and pre-funded warrants to purchase 4,931,506 shares at $18.2499 per warrant, with an exercise price of just $0.0001 per share.

Q32 Bio has also granted underwriters a 30‑day option to purchase up to 1,643,835 additional shares; the offering is expected to close around July 16, 2026, subject to customary closing conditions.

Net proceeds are intended for working capital and to fund research, clinical development, and commercialization efforts, including advancing its drug candidate bempikibart into future clinical trials.